National Abstract Competition for SCDAA’s 50th Annual Convention

Submissions are open.

DEADLINE: JUNE 30, 2022 

If you are a researcher, community-based member organization, physician, nurse, social worker or someone working on behalf of people living with sickle cell disease and their families, Sickle Cell Disease Association of America, Inc. would like to highlight your work at the 50th Annual National Convention October 11-15, 2022 (Virtual).

Because the convention will be virtual, those whose abstracts are accepted will have to submit a 5-minute pre-recorded video of their presentation. Presentations will be judged during “virtual poster walks,” which will include oral Q&A sessions after the video.

To be eligible, abstracts must meet guidelines and be submitted by June 30, 2022. Late submissions will not be accepted. Abstracts will be reviewed and ranked by the national abstract review committee. Abstract finalists will be judged during oral presentations and presented at the gala. “Best Abstract” in each category will be announced at the conclusion of the SCDAA 50th Annual National Convention. Special awards for the best student and trainee abstracts will also be given.

Submission Instructions and Guidelines

Abstract text must be written in English and contain the following:

TITLE: Use a concise title typed in CAPITAL LETTERS.

AUTHORS: List authors’ names (First name, middle initial, last name) and institutional affiliations as briefly as possible.

ABSTRACT TEXT:

  • Structure text utilizing the following subheadings: Objective, Methods, *Results, and Conclusions.
  • Submit abstracts in written form for scoring.
  • Authors can be modified to have less duplication of contact info for co-authors.

*Abstracts without results will not be accepted.

ABSTRACT CATEGORY: If your abstract seems to fit more than one category, please select a first choice and a second choice – the abstract judges will decide.

WORD COUNT: 1,000 maximum (no exceptions).

UPLOAD TABLES/CHARTS: One file per abstract submission (supported documents: PDF, PNG).

PRESENTATIONS: Presentation selected for the Q&A segment will be presented as video in groups of six abstracts for the “virtual poster walk,” with a faculty moderator.

2022 Topics and Examples

This year’s virtual convention will feature some innovations for the abstract presentations. To help focus the groups, four new topics have been added that are relevant to sickle cell disease in 2022. If your abstract seems to fit more than one category, please select a first choice and a second choice – the abstract judges will decide which category fits best.

Topic Examples for sickle cell disease (SCD)
Public Health, Policy, and Implementing the NASEM report Sickle Cell Blueprint for Action Describe ways to utilize the NASEM Report to promote SCD in Public Health, improve health policy on SCD, public awareness of SCD and SCT, health professionals’ awareness of SCD and SCT. Areas of interest include educational materials.
Community-Based Research Research that takes place in community settings and involves community members in the design and implementation of research projects, demonstrates respect for the contributions of success that are made by community partners.
Basic and Translational Research Mechanisms of SCD or SCT complications, scientific research to create new therapies, medical procedures, or diagnostics.
Clinical Research Human subjects research based in the clinic or hospital to study the safety, effectiveness, and/or efficacy of medications, devices, or diagnostic products for human use. These may be used for prevention, treatment, or diagnosis, or for relieving symptoms of SCD or SCT.
Psychosocial Research Psychosocial Research Research addressing the interrelation of behavioral, social, psychological, and other quality of life factors involving SCD or SCT. Areas of interest include Aging, caregiving, employment, health behaviors and fitness, independent living, self-management, and technology access.

Questions? Read our FAQ guide to learn more.
Submit your abstract here.